Bordeaux (France), November 16, 2020 – YSOPIA Bioscience, a French biotech company harnessing the properties of keystone single-strain bacteria to develop groundbreaking microbiome-based biotherapies, today announced that it has received funding approval from Bpifrance and the European Regional Development Fund through Nouvelle-Aquitaine Region for a total of €1.55M. This new funding will help drive YSOPIA’s biotherapeutics pipeline forward.
The company will receive €0.75M in funding from Bpifrance and a €0.8M grant from the Nouvelle-Aquitaine Region as part of an EU program to support regional competitiveness (ERDF). This funding will be used to advance the clinical development of the company’s lead biotherapy, Xla1, targeting obesity and associated metabolic diseases, and to support the preclinical development of another candidate addressing inflammatory bowel diseases (IBD). YSOPIA received initial funding from Bpifrance and the Nouvelle-Aquitaine Region in 2019.
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs grow their businesses and overcome the challenges they face (innovation, export…).
For more information, please visit our website: www.bpifrance.fr and presse.bpifrance.fr
Follow us on Twitter: @Bpifrance – @BpifrancePresse
In the same category
We are looking for a R&D Microbiologist
Oct 13, 2020more +
LNC Therapeutics becomes YSOPIA Bioscience marking its transition to a clinical stage company
Sep 29, 2020more +
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial...
Sep 8, 2020more +